Jazz Pharma officer plans $1.5M stock sale

Jazz Pharmaceuticals plc (JAZZ) officer Bruce C. Cozadd filed a Rule 144 notice for a planned sale of 6,000 shares of common stock through Merrill Lynch, with an aggregate market value of $1,500,780, expected on September 1, 2026 on NASDAQ.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) officer Bruce C. Cozadd filed a Rule 144 notice for a planned sale of 6,000 shares of common stock through Merrill Lynch, with an aggregate market value of $1,500,780, expected on September 1, 2026 on NASDAQ.

The filing also lists prior open-market sales of 6,000 shares each on June 1, July 1, and August 3, 2026.

Key Figures

Shares proposed to be sold: 6,000 shares Aggregate market value of proposed sale: $1,500,780 Proposed sale date: 09/01/2026 +3 more

6 metrics

Shares proposed to be sold 6,000 shares Common stock to be sold through Merrill Lynch on NASDAQ

Aggregate market value of proposed sale $1,500,780 Value associated with 6,000 shares in the planned Rule 144 sale

Proposed sale date 09/01/2026 Date listed for the Rule 144 transaction on NASDAQ

Past sale on 06/01/2026 6,000 shares for $1,410,720 Common stock sold by Bruce C. Cozadd during prior 3 months

Past sale on 07/01/2026 6,000 shares for $1,442,820 Common stock sold by Bruce C. Cozadd during prior 3 months

Past sale on 08/03/2026 6,000 shares for $1,517,880 Common stock sold by Bruce C. Cozadd during prior 3 months

Key Terms

Rule 144, Stock Option, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option financial

"Common | 02/26/2018 | Stock Option | Jazz Pharmaceuticals PLC"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

aggregate market value financial

"Common | Merrill Lynch ... | 6000 | 1500780 | 64914577"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for JAZZ?

It discloses that officer Bruce C. Cozadd filed a Rule 144 notice to sell 6,000 shares of Jazz Pharmaceuticals plc common stock through Merrill Lynch, with an aggregate market value of $1,500,780, expected to trade on NASDAQ on September 1, 2026.

How many JAZZ shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 6,000 shares of Jazz Pharmaceuticals plc common stock, to be sold through Merrill Lynch on NASDAQ, with an indicated aggregate market value of $1,500,780 as stated in the filing.

Who is selling JAZZ shares under Rule 144 in this filing?

The seller is Bruce C. Cozadd, identified as an officer of Jazz Pharmaceuticals plc. The filing lists him as the person for whose account the 6,000 shares of common stock are to be sold under Rule 144.

What past JAZZ stock sales by Bruce C. Cozadd are disclosed?

The filing lists three prior sales of 6,000 shares each of Jazz Pharmaceuticals plc common stock on June 1, 2026 for $1,410,720, July 1, 2026 for $1,442,820, and August 3, 2026 for $1,517,880.

What is the planned trade date and venue for the new JAZZ share sale?

The proposed sale of 6,000 shares of Jazz Pharmaceuticals plc common stock is listed with a date of September 1, 2026, with the securities to be sold on NASDAQ through Merrill Lynch.

What type of securities are underlying the JAZZ sale in this Form 144?

The filing identifies the securities as common stock of Jazz Pharmaceuticals plc. It notes that they relate to stock options granted on February 26, 2018, February 27, 2018, and March 1, 2018, with cash as the consideration method.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:22 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:21 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001193210
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Jazz Pharmaceuticals Plc
SEC File Number	001-33500
Address of Issuer	5th Floor Waterloo Exchange Waterloo Road Dublin IRELAND D04 E5W7
Phone	353-1-634-7800
Name of Person for Whose Account the Securities are To Be Sold	Bruce C Cozadd
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 3075A Hansen Way 1st Floor Palo Alto CA 94304	6000	1500780	64914577	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/26/2018	Stock Option	Jazz Pharmaceuticals PLC			2029	02/26/2018	Cash
Common	02/27/2018	Stock Option	Jazz Pharmaceuticals PLC			3700	02/27/2018	Cash
Common	03/01/2018	Stock Option	Jazz Pharmaceuticals PLC			271	03/01/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bruce Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin L2 D04-E5W7	Common	08/03/2026	6000	1517880
Bruce Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin L2 D04-E5W7	Common	07/01/2026	6000	1442820
Bruce Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin L2 D04-E5W7	Common	06/01/2026	6000	1410720

144: Remarks and Signature

Remarks
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Bruce C Cozadd
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)